Trogenix

Trial sites in the UK and US are open, and the first patient has been dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy.

The company develops precision cancer treatments through its proprietary gene therapy platform, Odysseus.

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain cancer.

Trogenix has dosed the first patient in a Phase I/II clinical trial of its **TGX-007 gene therapy**, a **Synthetic Super-Enhancers**-based treatment for **glioblastoma**. Preclinical tests showed **complete tumor elimination in 83% of cases** with no toxicity or recurrence over 11 months in a human-like brain cancer model.

May 2026TrogenixNews article

Trogenix’s **Synthetic Super-Enhancers** eliminate tumors in **83% of treated cases** of an aggressive brain cancer model resembling human glioblastoma. The single-dose treatment shows **no toxicity** over 11 months and **no tumor recurrence**. Results appear in *Nature*, highlighting potential for durable protection against brain cancer.

Apr 2026TrogenixNews article

Trogenix secures $95 million in Series A funding to accelerate clinical development of potentially curative therapies for aggressive solid tumors. The biotech company will advance its pipeline of innovative cancer treatments toward clinical trials. The funding supports rapid progress in targeting multiple tumor types with novel approaches.

Oct 2025TrogenixNews article

Trogenix wins **Startup of the Year** at the **Cancer Research Horizons 2025 Innovation & Entrepreneurship Awards**. The company leverages its **Odysseus gene therapy platform** to advance precision cancer treatments.

Jul 2025TrogenixNews article